Phase II study of sunitinib as second-line treatment for advanced gastric cancer. - Wikidata - wikimedia - TriplyDB

Phase II study of sunitinib as second-line treatment for advanced gastric cancer.

Phase II study of sunitinib as second-line treatment for advanced gastric cancer.

http://www.wikidata.org/entity/Q33389519

about

Critical appraisal of trastuzumab in treatment of advanced stomach cancer New advances in targeted gastric cancer treatment Current and emerging therapies in unresectable and recurrent gastric cancer Targeted therapy for advanced gastric cancer: A review of current status and future prospects Second-line treatment of metastatic gastric cancer: Current options and future directions Chemotherapy beyond second-line in advanced gastric cancer Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers Advances in targeted therapies and new promising targets in esophageal cancer Targeting receptor tyrosine kinases in gastric cancer Gastric Cancer: New Drugs - New Strategies Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.Sunitinib-associated pseudothrombocytopenia induced by IgM antibody.Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Molecular targeting to treat gastric cancer.Treatment options in patients with metastatic gastric cancer: current status and future perspectives Current status of novel agents in advanced gastroesophageal adenocarcinoma.Targeting metastatic upper gastrointestinal adenocarcinomas Targeting angiogenesis in esophagogastric adenocarcinoma.Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.Targeted therapy for esophagogastric cancers: a review Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer.Targeted therapy in gastroesophageal cancers: past, present and future.Targeted therapies in gastric cancer and future perspectives.Molecular targeted therapy for advanced gastric cancer Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.New and emerging combination therapies for esophageal cancer.Targeted therapy in gastric cancer.Targeted therapies for metastatic esophagogastric cancer Targeted therapies in the treatment of gastric cancer.Evolving standards of care in advanced gastric cancer.Second-line chemotherapy for advanced gastric cancer in Korea.Current status of targeted therapies in advanced gastric cancer.

P2860

Q24604411-B01B7232-4B07-41CE-B769-CCCA5BA31D44 Q26738548-9DAD6D4C-D161-4B74-9EEC-BDA2E1365F32 Q26745453-7F33D96B-FD89-49E0-BDBE-0CB128583772 Q26774138-564F2E2B-F53F-4D61-97BB-21301EBF042D Q26778027-D4F5C1B6-85EB-498A-91A8-3EFC8AE36ED4 Q26798288-007F61AC-F6E7-43EC-A4AF-9301ABBBB26D Q26801289-9FCD660E-7271-426C-B155-DA4887D3CAA5 Q26825957-EB4B0756-832E-40B8-94DC-9F751BD67C23 Q27013050-EF47C763-3387-4ADB-9F7F-1A60AA3BCDA6 Q27028079-DB03AC2F-EACF-49F9-AF72-10C40E544E63 Q28079362-C593D5F8-0EA4-4579-BD4A-E12992CFD04A Q28082921-FB73B434-AFD2-49B3-9583-AFBA9F9CA72F Q28544422-983872A3-C89A-4735-8C10-161ED024B52B Q30313895-8AB43056-60D9-4E17-8991-1A8F4CE39E7E Q33403806-EB840E42-1698-4B7C-9CDB-DD038DD7D84F Q33407676-B1F0465A-C514-47F2-AA29-145932D46987 Q33420495-DFE7CFDF-9682-4775-8DA7-EC340AA58726 Q33633424-E1552C7F-C69E-44CB-B3AC-0496942AB3DE Q34326593-62EBBE44-32C1-4CF5-96C6-D9C94C13E564 Q34661367-8CD61FD4-E7BB-4670-A07A-972088F1AADC Q34962039-A1BC5CD1-C503-4306-AFEF-AC9D510673F1 Q35000785-8F488BC0-B8E8-46CF-B4BF-9E3A8D0F353A Q35584958-F72DD2CD-2643-4880-B33A-A80402FD631C Q35640101-49347EFD-2FA5-437E-A74A-8F7EDC284D38 Q35863874-CC558694-4A79-4E6B-A2AD-5CBA0CD175C9 Q35927364-955A0D32-BECA-4012-892F-60FCD90F7E44 Q36039645-1E1D6925-07EA-4DB4-8600-92EAF23BC0CB Q36223964-6722C7E2-FA6C-4055-AEBE-3468B32AB38D Q36280358-2CB01D33-01C1-4B20-9B54-76DD9BB0E3D0 Q36294579-B1084436-B69D-492B-82F5-5EFD20504A52 Q36471685-840744D6-65BE-4E19-AABB-F93D41A6E651 Q36705689-56E77F41-A7EA-4664-AAB0-437843470701 Q36799684-D2FB57E7-CF99-4E1B-A17D-90E1F8999C9A Q36996728-8B3DDE7C-57E1-4428-B463-4EC19BE36C11 Q37341824-E8C677B6-F584-4F2C-BCC5-799743C5018D Q37836513-7D28940C-1819-478E-99D5-51DFDF591395 Q37925131-7DA78594-4993-4C2F-9E31-CC53983A1743 Q37960206-F6F2A9FD-02C1-43EF-9138-F159AE9AF3DB Q37992841-D0C9AEB5-ABB4-44E2-A20D-8B859800BF88 Q37996448-EA1DB6A1-06C2-4A4A-8652-34BFD6058A0B

P2860

Phase II study of sunitinib as second-line treatment for advanced gastric cancer.

http://www.wikidata.org/entity/Q33389519

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase II study of sunitinib as second-line treatment for advanced gastric cancer.

@ast

Phase II study of sunitinib as second-line treatment for advanced gastric cancer.

@en

type

label

Phase II study of sunitinib as second-line treatment for advanced gastric cancer.

@ast

Phase II study of sunitinib as second-line treatment for advanced gastric cancer.

@en

prefLabel

Phase II study of sunitinib as second-line treatment for advanced gastric cancer.

@ast

Phase II study of sunitinib as second-line treatment for advanced gastric cancer.

@en

P1433

Q33389519-7C6AA698-9F5B-440A-84F7-C34C88F872F3

P1476

Q33389519-26236083-4F65-4442-ABB2-2B76CD760EEC

P2093

Q33389519-000F987C-6DB5-4FEA-B6B0-50008F54C263

Q33389519-03DF5922-742E-4460-8AE9-7FA9311E2116

Q33389519-0E16BA12-F7CF-48A4-A0EA-435159C8E6A5

Q33389519-0E5706C5-E399-4D2E-9D4C-F0E67D491E2D

Q33389519-16B9D243-F0B5-42F7-83A0-D0EF5372D49F

Q33389519-1BD935DC-1FC5-4898-8641-0B46057FFDF7

Q33389519-2B1059FB-87E2-4E1D-A997-D05F1795C0ED

Q33389519-3EBA9399-3817-426D-81AC-422893C614D7

Q33389519-52CEA201-9A6E-4537-96A3-808B46F18819

Q33389519-59221C0D-DE78-47CB-B242-4279D39D729F

P2860

Q33389519-0B78714E-AE07-49DA-81B3-FDA70D8AE146

Q33389519-12C9F4EF-8388-4005-8DA6-35450CE0CC5E

Q33389519-1F6B64E3-C7EB-42C5-9CB5-A739FAA939D6

Q33389519-3270AB20-532C-48F7-BD8D-A06F10A20759

Q33389519-33952CF0-F9D1-4B30-85DE-4CCF38EFB892

Q33389519-34C4212A-C2B4-4130-AE05-BEF8C2068648

Q33389519-36991318-9DC9-4C10-9966-2E5E07036229

Q33389519-422A4041-B460-4B2B-90FB-C034D57E33E2

Q33389519-454BE91B-72E1-4E56-A808-16733004412D

Q33389519-51EC7CA5-667E-45EE-882F-7B5947294D95

P2888

Q33389519-5C4444F1-AB06-4077-BB22-506D2E5730D5

P304

Q33389519-BE45D058-80D3-4C8B-8023-B87BABB12BBF

P31

Q33389519-308754F5-EF84-4D1C-A616-6A864487933B

P356

Q33389519-B43C88A4-0B15-4A21-A77F-FA676275A5F3

P433

Q33389519-5299F043-C5B0-474B-AA4A-3B42BBE2E042

P478

Q33389519-4893C1C8-CFCC-46CA-A372-1172FAF8DBDE

P50

Q33389519-111025D4-1FC5-49B7-A91F-6F6D22DB1ABF

Q33389519-B5D45A05-587B-44FB-A14C-5DA6FE0B2522

P577

Q33389519-1105DF1C-3D33-4B19-ADDA-A73E59A5D904

P5875

Q33389519-39D76C50-8767-4C75-94B4-6CE5B7E251CF

P6179

Q33389519-9B687DF0-F71A-433C-AEB5-31929D10F1EF

P698

Q33389519-968B53FF-B350-4588-A977-3837B42F66E2

P932

Q33389519-ECB5984A-6BF7-460A-AA9C-8C510BFB1AD6

P356

S10637-010-9438-Y

P1433

Investigational New Drugs

P1476

Phase II study of sunitinib as second-line treatment for advanced gastric cancer.

@en

P2093

Alberto Sobrero

http://www.w3.org/2001/XMLSchema#string

Dongrui Ray Lu

http://www.w3.org/2001/XMLSchema#string

Hyun C Chung

http://www.w3.org/2001/XMLSchema#string

Jen-Shi Chen

http://www.w3.org/2001/XMLSchema#string

Jennifer M Tursi

http://www.w3.org/2001/XMLSchema#string

Lin Shen

http://www.w3.org/2001/XMLSchema#string

Maria J Lechuga

http://www.w3.org/2001/XMLSchema#string

Narikazu Boku

http://www.w3.org/2001/XMLSchema#string

Shukui Qin

http://www.w3.org/2001/XMLSchema#string

Wai-Tong Ng

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Epidemiology of gastric cancer in Japan.

P2888

s10637-010-9438-y

P304

1449-1458

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-010-9438-Y

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Ana Ruiz-Garcia

P577

2010-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44591143

http://www.w3.org/2001/XMLSchema#string

P6179

1037371356

http://www.w3.org/2001/XMLSchema#string

P698

20461441

http://www.w3.org/2001/XMLSchema#string

P932

3171673

http://www.w3.org/2001/XMLSchema#string